Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Showing 20 of 25369 trials
Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression
NCT07645157
Recruiting
Conditions Major Depressive Disorder (MDD), Probiot...
Phase PHASE2
Enrollment 120
Locations 1 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this clinical trial is to evaluate the efficacy and safety of sertraline combined with multi-strain probiotics in adolescents aged 12-18 with major depressive disorder. The primary research question is whether sertraline combined with multi-strain probiotics is superior to sertraline combined with placebo in alleviating depressive symptoms and improving mood symptoms in adolescents. If there is a control group: researchers will compare sertraline combined with multi-strain probiotics with sertraline combined with placebo (a substance that looks similar but does not contain probiotics) to determine whether adding multi-strain probiotics provides greater therapeutic benefits for adolescent patients with depression. Participants will: 1. Undergo 8 weeks of treatment with sertraline combined with multi-strain probiotics or sertraline combined with placebo; 2. Have clinical visits every 4 weeks for clinical assessments and safety monitoring.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Sertraline — Weeks 1-4, the starting dose of sertraline is 25 mg/day, adjusted according to the clinical assessment of the psychiatrist, with a dosage range of 25-150 mg/day. By week 4, the sertraline dosage should reach at least 150 mg/day; placebo powder, 1 sachet/day.

Primary Outcomes

  • Change in Children's Depression Rating Scale - Revised (CDRS-R) scores (Assessments will be performed at baseline, week 4, and week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-10-01
Completion: 2028-10-01
Eligibility
Age: 12 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Chongqing Medical University
Contact Information
Study Contact:
Teng Teng
+86 18883368354
tengteng@hospital.cqmu.edu.cn
Interventions
  • Drug: Sertraline — Weeks 1-4, the starting dose of sertraline is 25 mg/day, adjusted according to the clinical assessment of the psychiatrist, with a dosage range of 25-150 mg/day. By week 4, the sertraline dosage should reach at least 150 mg/day; placebo powder, 1 sachet/day.
Study Locations (1 sites)
The Affiliated Hospital of Chongqing Medical University, Chongqing, Yuzhong 400010 China
Eligibility Criteria
Inclusion Criteria: * • Aged 12-18 years * Meets DSM-5 criteria for major depressive disorder (MDD) and is currently in a depressive episode according to the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL) interviews * Child Depression Rating Scale-Revised (CDRS-R) score ≥40 at baseline * Clinical Global Impression Scale (CGI-S) score ≥ 4 at baseline Exclusion Criteria: * • Presence of any comorbid psychiatric disorder according to DSM-5, other than anxiety disorders * MDD with psychotic symptoms * Young Mania Rating Scale (YMRS) \>13 at baseline * History of neurological disorders (e.g., epilepsy, traumatic brain injury), or the presence of serious physical illnesses (e.g., thyroid disease, lupus erythematosus, diabetes mellitus, clinically significant pulmonary, hepatic, or renal impairment, or major trauma) * Nonresponse to at least two antidepressants with different mechanisms, and each administered at an adequate dose and for an adequate duration * History of intolerance to sertraline or nonresponse to an adequate therapeutic course of sertraline * Current high suicide risk * History of alcohol or drug abuse or dependence * Taking or administering antidepressants within 5 half-lives * Use of probiotic-related food or medicine within 2 weeks before enrollment * Systemic use of antibiotics or antifungals within 1 month before enrollment * History of severe food allergy or known hypersensitivity to the Lactobacillus crispatus preparation or any of its components * Adherence to vegetarian or other restrictive dietary patterns * Pregnancy or breastfeeding
Effect of Music Activities on Depression and Sleep Quality in Frail Older Adults
NCT07049445
Not yet recruiting
Conditions Depression, Sleep Quality, Frailty
Phase NA
Enrollment 80
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to examine the effects of music activities on depression and sleep quality among frail older adults, and to develop a standardized music activity protocol suitable for use in adult day care centers. A randomized controlled trial (RCT) design will be used. Participants will be recruited from 4 to 5 adult day care centers and randomly assigned to either an intervention group (receiving music activities twice per week, one hour per session, for eight weeks) or a control group (receiving only routine activities). Depression and sleep quality will be measured at baseline, week 4, and week 8. Assessments will include validated questionnaires and the index of osteoporotic fractures. Data analysis will evaluate the effectiveness of music activities in improving depression and enhancing sleep quality.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Music Activity Program — Participants in the experimental group will receive the standard day care center activities plus a music activity intervention. The music activity consists of pre-recorded video sessions conducted twice a week, each lasting one hour, for a total duration of 8 weeks.

Primary Outcomes

  • Geriatric Depression Scale-15 (GDS-15) (At baseline, week 4, and week 8)
  • Pittsburgh Sleep Quality Index (PSQI) (At baseline, week 4, and week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2025-09-01
Completion: 2027-06-30
Eligibility
Age: 60 Years
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Chung Hsing University
Contact Information
Study Contact:
Chia-Te Chen
04 2284 0360-813
a0911395524@dragon.nchu.edu.tw
Interventions
  • Behavioral: Music Activity Program — Participants in the experimental group will receive the standard day care center activities plus a music activity intervention. The music activity consists of pre-recorded video sessions conducted twice a week, each lasting one hour, for a total duration of 8 weeks.
Study Locations (1 sites)
huajiale Day Care Center, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: * Inclusion Criteria: 1. Aged 60 years or older. 2. Currently receiving services at an adult day care center. 3. Frailty score ≥1 based on the Study of Osteoporotic Fractures (SOF) index. 4. Geriatric Depression Scale (GDS-15) score ≥5 or Pittsburgh Sleep Quality Index (PSQI) score ≥5. 5. Clear consciousness and able to communicate in Mandarin or Taiwanese. Exclusion Criteria: 1. Severe hearing or visual impairments. 2. Diagnosed with severe psychiatric disorders or dementia. 3. Unable to participate in group activities.
Essential Coaching for Every Mother in Tanzania
NCT05362305
Active, positions filled
Conditions Parenting Self Efficacy, Postpartum Depr...
Phase NA
Enrollment 124
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate a text message intervention called Essential Coaching for Every Mother in Tanzania to improve mothers' access to essential newborn care information during the immediate six-week postnatal period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Essential Coaching for Every Mother — Daily text messages for the first six-weeks postpartum.

Primary Outcomes

  • Newborn Care Knowledge (Baseline (enrolment), and six-weeks postpartum (follow-up))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2024-06-13
Completion: 2025-10-10
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: true
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IWK Health Centre
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Behavioral: Essential Coaching for Every Mother — Daily text messages for the first six-weeks postpartum.
Study Locations (1 sites)
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Eligibility Criteria
Inclusion Criteria: * have recently given birth within the hospital within 48 hours * have daily access to a mobile phone with text message capabilities * are over 18 years of age * speak and read English or Swahili. Exclusion Criteria: * newborns die or are expected to die prior to leaving the hospital * they have no access to mobile phone, either personal or shared * unwilling to receive text messages * decline to participate * are experiencing major postnatal complications expected to impact learning or ability to consent while in the hospital (e.g., postpartum hemorrhage, seizures) * participated in Phase I of this project.
Effects of HIIT and MICT Training on Cardiorespiratory Fitness, Testosterone/Cortisol Ratio, and Mental Health in Young Adults
NCT07397702
Not yet recruiting
Conditions Exercise
Phase NA
Enrollment 76
Locations 0 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study will use a randomized, double-blind clinical trial to evaluate the effects of eight-week HIIT and MICT exercise programs on cardiorespiratory fitness, the testosterone/cortisol ratio, and mental health in 68 healthy, moderately active young adults aged 18 to 21. Participants will be assigned to parallel groups based on their sex and training type (HIIT men, HIIT women, MICT men, MICT women). The key metrics will be measured both before and after the intervention period to assess the impact of the different training regimens.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Other: High-intensity interval training — The intervention involves physical exercise with the aim of observing any changes that may occur in mental health and hormonal parameters. However, the magnitude of these effects and the type of exercise that is most effective in reducing symptoms of anxiety and depression are still unknown.
  • Other: Moderate-intensity continuous training — The intervention involves physical exercise with the aim of observing any changes that may occur in mental health and hormonal parameters. However, the magnitude of these effects and the type of exercise that is most effective in reducing symptoms of anxiety and depression are still unknown.

Primary Outcomes

  • Symptoms of anxiety from baseline to eight weeks. (Baseline and week 8 of training.)
  • Symptoms of depression from baseline to eight weeks. (Baseline and week 8 of training.)
  • Testosterone levels using the ELISA method (Baseline and week 8 of training.)
  • Cortisol levels using the ELISA method (Baseline and week 8 of training.)
  • Cardiorespiratory capacity using VO₂max (Baseline and week 8 of training.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-05-25
Completion: 2026-08-07
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 76 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidad de Colima
Principal Investigators:
  • Pedro Julián Flores Moreno (STUDY_CHAIR) - Universidad de Colima
Contact Information
Study Contact:
Luis Jaime Orozco Milanez, M. Sc.
+(52) 312 209 5656
lorozco2@ucol.mx
Interventions
  • Other: High-intensity interval training — The intervention involves physical exercise with the aim of observing any changes that may occur in mental health and hormonal parameters. However, the magnitude of these effects and the type of exercise that is most effective in reducing symptoms of anxiety and depression are still unknown.
  • Other: Moderate-intensity continuous training — The intervention involves physical exercise with the aim of observing any changes that may occur in mental health and hormonal parameters. However, the magnitude of these effects and the type of exercise that is most effective in reducing symptoms of anxiety and depression are still unknown.
Eligibility Criteria
Inclusion criteria: * Men and women aged 18 to 21. * Lead a sedentary or moderately active lifestyle (IPAQ ≤600 METs-min/week). * Subjects diagnosed by a physician as fit for physical exercise. * Informed consent form signed by the study subjects. Exclusion criteria: * Subjects with any motor disability. * Pregnant women. * Subjects with metabolic disorders. * Subjects with chronic respiratory diseases such as asthma, emphysema, or cancer, obstructive pulmonary disease. * Subjects with high blood pressure or arrhythmia. * Failure to sign the informed consent form. * Subjects who are in a high-performance physical training program. * Women with irregular menstrual cycles who take contraceptive medication to regulate their menstrual cycle. * Consumption of caffeine, alcohol, and tobacco or use of electronic cigarettes. * Subjects with a cyclical diagnosis of anxiety and depression by a specialist. * Frequent consumption of alcoholic beverages (more than 7 drinks per week for women and more than 14 drinks per week for men) or a history of excessive alcohol consumption. * Subjects who consume dietary supplements (caffeine, nitric oxide precursors, beta-alanine, creatine, sodium bicarbonate, or L-carnitine). Elimination criteria: * Voluntary withdrawal from the study. * Attendance at less than 80% of intervention sessions. * Incomplete measurement schedule or insufficient sample size. * Joint or muscle injuries caused by the training program. * Overtraining syndrome.
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
NCT07300969
Recruiting
Conditions Major Depressive Disorder (MDD)
Phase PHASE2
Enrollment 300
Locations 43 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: DT-101 — DT-101 A
  • Drug: DT-101 — DT-101 B
  • Drug: Placebo — Placebo

Primary Outcomes

  • Change from baseline in total Montgomery Åsberg depression rating scale (MADRS) score, at Day 42 (from enrollment to day 42)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-12-16
Completion: 2027-08
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Draig Therapeutics Ltd
Contact Information
Study Contact:
Chief Medical Officer
+44(0)2920028450
info@draigtherapeutics.com
Interventions
  • Drug: DT-101 — DT-101 A
  • Drug: DT-101 — DT-101 B
  • Drug: Placebo — Placebo
Study Locations (43 sites)
Draig Clinical Site, Bentonville, Arkansas 72712 United States
Draig Clinical Site, Little Rock, Arkansas 72211 United States
Draig Clinical Site, Oceanside, California 92056 United States
Draig Clinical Site, San Diego, California 92103 United States
Draig Clinical Site, Torrance, California 90502 United States
Draig Clinical Site, Miami, Florida 33166 United States
Draig Clinical Site, New Port Richey, Florida 34652 United States
Draig Clinical Site, Orlando, Florida 32803 United States
Draig Clinical Site, Atlanta, Georgia 30331 United States
Draig Clinical Site, Decatur, Georgia 30030 United States
Eligibility Criteria
Inclusion Criteria: * The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent * Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent. * Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022). Exclusion Criteria: * Pregnant or breastfeeding or plans to become pregnant during the study. * Unstable medical condition or unstable chronic disease. * Significant neurological abnormality. * History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening. * History of seizure. * In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.
JoyPop Mobile Mental Health App With Transitional-Aged Youth
NCT06239545
Recruiting
Conditions Emotion Regulation, Depression, Anxiety,...
Phase NA
Enrollment 110
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

New challenges, stressors, and a loss of support often accompany the transition from adolescence to adulthood. Not surprisingly, transitional-aged youth (TAY) between the ages of 18-25 experience some of the highest rates of mental distress. However, access to mental health services diminish for TAY due to gaps in care when transitioning from pediatric to adult services. These challenges are exacerbated in rural communities, such as in Northwestern Ontario, where youth already access mental health services less frequently and face longer wait times than those in more urban areas. Limited access and extended waits can exacerbate symptoms, prolong distress, and increase the risk for adverse outcomes. Novel, innovative approaches are urgently needed to support TAY in Northwestern Ontario. In partnership with St. Joseph Care Group and Thunder Bay Counselling Centre, the investigators are evaluating the impact of a mental health app (JoyPop) as a tool for TAY waiting for mental health services. The JoyPop app was developed to support improved emotion regulation - a fundamental difficulty for youth presenting with mental health challenges. A two-arm randomized controlled trial (RCT) will be used to evaluate the effectiveness of the app compared to usual practice while TAY are waiting for mental health services.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Usual Practice + JoyPop — Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.

Primary Outcomes

  • Change in emotion regulation (overall) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (strategies) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (non-acceptance) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (impulse) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (goals) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (awareness) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (clarity) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-01
Completion: 2025-12
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lakehead University
Contact Information
Study Contact:
Aislin R Mushquash, PhD
807-343-8010
aislin.mushquash@lakeheadu.ca
Interventions
  • Behavioral: Usual Practice + JoyPop — Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
Study Locations (1 sites)
Lakehead University, Thunder Bay, Ontario P7B5E1 Canada
Eligibility Criteria
Inclusion Criteria: * Youth must be on the wait-list for mental health services at St. Joseph's Care Group or Thunder Bay Counselling Centre and be between 18-25 years old. * Eligible youth will also need to be available to attend a virtual or in-person orientation session. * In order to download the JoyPop app, participants will need access to an iOS device (e.g., iPhone, iPad). Refurbished iPhones containing just the JoyPop app will be provided to participants to use for the duration of the trial if they do not have access to their own.
PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.
NCT07095205
Recruiting
Conditions Major Depressive Disorder (MDD)
Phase PHASE4
Enrollment 14
Locations 1 sites
Compensation Phase 4: Typically $100-$500
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment.

Design

Study type: Interventional Phases: Phase4 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Nicotine transdermal patch — The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).
  • Drug: PET Scan with [18F] VAT — All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.

Primary Outcomes

  • Change in Hamilton Depression Rating Scale-17 (HAMD) score. (Before and after 8 days of treatment with nicotine.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-10-03
Completion: 2029-09-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 14 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stony Brook University
Collaborators: National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Principal Investigators:
  • Ramin Parsey, MD, PhD (PRINCIPAL_INVESTIGATOR) - Stony Brook University
Contact Information
Study Contact:
Julianna Lizzul
631-638-0291
julianna.lizzul@stonybrookmedicine.edu
Interventions
  • Drug: Nicotine transdermal patch — The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).
  • Drug: PET Scan with [18F] VAT — All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.
Study Locations (1 sites)
Stony Brook University: Dept of Psychiatry, Stony Brook, New York 11794 United States
Eligibility Criteria
Inclusion Criteria: For Non-Depressed Participants: * Age range 18 to 65 years old. * Capacity to consent (able to read, understand, and sign informed consent). For Participants with MDD * Age range 18 to 65 years old. * Capacity to consent (able to read, understand, and sign informed consent). * Major Depressive Disorder (MDD) as primary diagnosis and currently in a major depressive episode * Score of at least 29 on the Montgomery-Asberg Depression Rating Scale (MADRS). Exclusion Criteria: For Non-Depressed Participants: * Nicotine use, including tobacco, e-cigarettes, nicotine patch, nicotine gum, within the past year \[except for occasional users, who cannot use nicotine products in the week before the scan\]. * Need for use of medication during the study that will affect cholinergic levels. * Problematic drug/alcohol use that is judged sufficient to interfere with study procedures during the treatment period or impact participant safety. * Significant active physical illness or neurological deficit that may affect brain function or imaging. * Significant eye conditions such as keratoconus and/or need for rigid contact lenses. * Current or lifetime history of a major psychiatric diagnosis. * Any MRI contraindications, including recent tattoos, metal implants, pacemaker, metal prostheses, orthodontic appliances, or presence of shrapnel that are contraindicated for MRI. * Any PET contraindications, including if study imaging will result in the participant receiving greater exposure than the research limit, or if participant is pregnant, currently breastfeeding, or planning to conceive during the course of study participation. * Blood donation within 8 weeks of the \[18F\]VAT scan. For Participants with MDD * Nicotine use, including tobacco, e-cigarettes, nicotine patch, nicotine gum, within the past year \[except for occasional users, who cannot use nicotine products in the week before the scan\]. * Currently on effective antidepressant medications or need for use of medications that target the cholinergic system. * Problematic drug/alcohol use that is judged sufficient to interfere with study procedures during the treatment period or impact participant safety. * Significant active physical illness or neurological deficit that may affect the brain function or imaging. * Significant eye conditions such as keratoconus and/or need for rigid contact lenses. * Current or lifetime major psychiatric diagnosis other than MDD. * Life-time history of psychosis or current psychosis. * Significant risk for suicide. * Any MRI contraindications, including recent tattoos, metal implants, pacemaker, metal prostheses, orthodontic appliances, or presence of shrapnel that are contraindicated for MRI. * Any PET contraindications, including if study imaging will result in the participant receiving greater exposure than the research limit, or if participant is pregnant, currently breastfeeding, or planning to conceive during the course of study participation. * Blood donation within 8 weeks of the \[18F\]VAT scan.
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
NCT07610369
Recruiting
Conditions Depression, Parkinson's Disease (PD)
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Psilocybin (drug) — Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring
  • Drug: Psilocybin (drug) — Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring

Primary Outcomes

  • Change in depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) (Baseline to 30 days after first drug dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07
Completion: 2030-07
Eligibility
Age: 40 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: Michael J. Fox Foundation for Parkinson's Research
Principal Investigators:
  • Sophie Holmes, PhD (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Sophie Holmes, PhD
203-685-4066
sophie.holmes@yale.edu
Gerard Sanacora, MD
gerard.sanacora@yale.edu
Interventions
  • Drug: Psilocybin (drug) — Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring
  • Drug: Psilocybin (drug) — Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring
Study Locations (1 sites)
Yale University, New Haven, Connecticut 06510 United States
Eligibility Criteria
Inclusion Criteria: * Able to understand and provide informed consent * Comfortable speaking and writing in English * Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect) * Have no changes in medication or major surgical procedures anticipated for treatment duration * Have a score \>/=20 on the Beck Depression Inventory-2 (BDI-2), consistent with moderate or greater depressive symptom severity, at Baseline. * For people who can become pregnant: agree to use highly effective contraception from entry into the trial through Day B30 assessments (4 weeks after the second psilocybin administration session) and agree to not breastfeed. Acceptable methods of contraception are: An intrauterine device (IUD), hormone-based contraceptives (birth control pills) , condoms (internal or external) must be used with another method (other than spermicide), and complete abstinence from sexual activity that could result in pregnancy. * Agree that for one week preceding each psilocybin session, they will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the research team. Exceptions will be evaluated by the research team and assessed for safety. Agree to abstain from all tobacco and nicotine use for the duration of the study. * Agree to consume approximately the same amount of caffeine-containing beverages that they usually consume before arriving at the research unit on the mornings of psilocybin administration sessions. * Agree to avoid sedative-hypnotic medications (e.g., benzodiazepines, zolpidem, zopiclone, zaleplon) taken on an as-needed basis for a minimum of 5 half-lives prior to each psilocybin administration session and for 24 hours after each psilocybin administration session. * Agree to avoid opioid medications taken on an as-needed basis for a minimum of 5 half-lives prior to each psilocybin administration session and for 24 hours after each psilocybin administration session. * Agree not to use products or substances containing Δ9-tetrahydrocannabinol (THC) and/or cannabidiol for at least 7 days prior to each psilocybin administration session and for 24 hours after each psilocybin administration session. * Agree to not use non-prescribed narcotics (eg. heroine, fentanyl), depressants (eg. Barbiturates, benzodiazepines) and/or inhalants for the duration of participation in the trial. * Agree not to consume alcoholic beverages for at least 24 hours prior to and 24 hours following each psilocybin administration session. * Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating care and is available for consultation with the study medical monitor. Exclusion Criteria: * Any indication of forms of parkinsonism other than idiopathic Parkinson's disease. * Cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score \<24. * Symptomatic orthostatic hypotension. * Currently receiving electroconvulsive therapy (ECT) or treatment via transcranial magnetic stimulation (TMS). Previous treatment with ECT and/or TMS is permitted; last treatment must be at least 30 days prior to entry into this trial. * Treatment in a clinical trial within 30 days of entry into this trial or treatment with another investigational drug or other intervention within 30 days or 5 half-lives, whichever is longer, prior to entry into this trial. * Pregnancy as indicated by a positive urine pregnancy test during screening, lactation, or the intention of becoming pregnant within 3 months of entry into this trial. * Current severity of psychiatric symptoms warranting immediate treatment as determined by the study medical staff (e.g. due to inability to provide for basic needs/safety). The study medical staff will assess these individuals, determine the appropriate level of care, and coordinate with the individual's primary providers to ensure close follow-up. * High risk of self-harm/suicide, as determined by the Columbia-Suicide Severity Rating Scale (C-SSRS) risk screen, specifically: participant answers "yes" to item 4 or 5 suggesting intent to act on suicidal thoughts OR participant has made a serious suicide attempt within the 12 months prior to entry into this trial. * History of meeting DSM-5 criteria for a schizophrenia spectrum disorder, other psychotic disorder, or a mood disorder with psychotic features. * History of delusional symptoms or any other psychotic symptoms accompanied by a loss of insight. Exceptions may be made at the investigators' discretion in cases of a history of psychotic symptoms that were attributable to substance or medication use. * Current delusional symptoms or any other psychotic symptoms accompanied by a loss of insight. * History of a schizophrenia spectrum disorder in a first-degree relative. * History of bipolar disorder 1 in a first-degree relative, in whom illness onset was prior to age 40. * Current or history of meeting DSM-5 criteria for a bipolar disorder. * Current or history within the last 2 years of meeting DSM-5 criteria for a moderate or severe alcohol or drug use disorder, excluding caffeine. * Currently meeting DSM-5 criteria for another psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin treatment procedures as determined by the investigators. * History of meeting DSM-5 criteria for Hallucinogen Persisting Perception Disorder (HPPD). * History of using any psychedelic substances including psilocybin, lysergic acid diethylamide (LSD), mescaline (and natural products containing mescaline including peyote and San Pedro cactus), N,N-Dimethyltryptamine (DMT), natural products containing DMT including ayahuasca and 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), ibogaine, 2C compounds, 3,4-methylenedioxy-methamphetamine (MDMA), or methylone during the past 6 months at dosages and/or frequencies determined clinically significant by the investigators. * Cancer with known central nervous system (CNS) involvement, CNS infection, or other major CNS disease aside from PD. * Epilepsy or other seizure disorder in adulthood. * Supplemental oxygen requirement. * Allergy or intolerance to any of the materials contained in the drug products. * Renal insufficiency defined as creatinine clearance \< 40 ml/min using Cockraft and Gault equation * Insufficiently managed endocrine conditions, including diabetes mellitus and clinically significant thyroid dysfunction. * Cardiovascular conditions, including: * Elevated blood pressure defined as systolic blood pressure (SBP) \>150 or diastolic blood pressure (DBP) \>95 taken during Enrollment * Tachycardia defined as heart rate (HR) \>90 beats per minute taken during Enrollment * Bradycardia defined as HR \<50 bpm taken during Enrollment * Angina * History of stroke within the past year * Clinically significant ECG abnormality as determined by the investigators, including but not limited to QTc \> 450 * Hepatic dysfunction as indicated by any of the following laboratory values: * AST \> 3 x upper limit of normal * ALT \> 3 x upper limit of normal * Total bilirubin \> 3.0 mg/dl * Use of any of the following concomitant medications AND inability/unwillingness to discontinue for at least 5 times the elimination half-life of the agent (specific exceptions are noted) prior to psilocybin administration, including: * Agents that may be associated with serotonin syndrome: * MAO inhibitors (participants must have discontinued 2 weeks prior to baseline) * St. John's Wort * S-adenosyl-methionine (SAM-e) * 5-Hydroxytryptophan (5-HTP) * Dextromethorphan * Opioids (e.g., codeine, fentanyl, hydrocodone, meperidine, tramadol) * Lithium * Linezolid * Buspirone * Agents that may interact with psilocybin metabolism/effects:
A-B-C Program for Sedentary Older Adults With Depressive Symptoms
NCT07176637
Not yet recruiting
Conditions Sedentary Older Adults, Sedentariness an...
Phase NA
Enrollment 66
Locations 0 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The importance and benefits of leading a physically active lifestyle have been long studied. Examples of the multiple advantages from physical activity are improved health of the heart and brain, having a more independent living and better quality of life. However, it is known that for many people, being active is challenging: physical activity is commonly viewed as a burden or inconvenience. In this study we will explore how some common everyday thoughts are hurdles to becoming physically active. We will discover ways to overcome this by using concepts from a field called "behavioral economics" that explains how we make decisions. The purpose of the program is to support participants in being more physically active. The study program is a newly developed way to overcome the intuitive preference for being sedentary. The experimental groups will learn simple ways to overcome expected hurdles in making decisions related to physical activity (the newly developed program), and the control groups will learn about the health benefits of physical activity and the health guidelines (the common practice today). We will compare the effectiveness of the newly developed intervention in promoting an active lifestyle, compared to the common practice today, of providing the knowledge and the recommended guidelines. The program in the study will be in small groups of 5-10 participants that will meet at The Royal for 60 minutes, twice a week, for 4 weeks.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: A-B-C Program — The purpose of this study is to assess the effectiveness of the 4-week "A-B-C" program in implementing and maintaining daily PA. We will explore outcomes for the effectiveness of the program, on (1) increasing the weekly duration of PA, and (2) reducing baseline depressive symptoms and other mental health outcomes among sedentary older adults with depressive symptoms at baseline. Specifically, we will evaluate the change in depressive symptoms, stress, and self-esteem from baseline, at the end of the 4-week intervention, and after additional 4 weeks from the end of the intervention (at follow-up). The intervention will be 4 weeks overall, with total of 8 sessions: the duration of each session will be 60 minutes each, and the frequency will be twice weekly for 4 weeks.
  • Other: Physical Activity Educational Program — The control group will serve as an sham active comparator, designed to control for group format, scheduled sessions, and social interaction. The agenda for the control group was designed to specifically function as a control to compare the A-B-C program. These participants will also attend twice-weekly 60-minute sessions over four weeks, focusing on educational content about the health benefits of physical activity and current physical activity guidelines. The difference between the two interventions is that the control program is strictly educational, whereas the A-B-C program focuses on challenging cognitive biases that change decision making related to physical activity. To reiterate, the control program simply provides education on the effects of physical activity with physiological evidence.

Primary Outcomes

  • Daily dose of PA (From enrollment to the end of treatment at 4 weeks (post-intervention); every 3 months up to 12 months post-intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2025-09
Completion: 2026-12
Eligibility
Age: 65 Years
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Royal Ottawa Mental Health Centre
Contact Information
Study Contact:
Sivan Klil-Drori, MD
(613) 722-6521
sivan.klil-drori@theroyal.ca
Anvita D Gupta, MSc
(613) 722-6521
anvita.gupta@theroyal.ca
Interventions
  • Behavioral: A-B-C Program — The purpose of this study is to assess the effectiveness of the 4-week "A-B-C" program in implementing and maintaining daily PA. We will explore outcomes for the effectiveness of the program, on (1) increasing the weekly duration of PA, and (2) reducing baseline depressive symptoms and other mental health outcomes among sedentary older adults with depressive symptoms at baseline. Specifically, we will evaluate the change in depressive symptoms, stress, and self-esteem from baseline, at the end of the 4-week intervention, and after additional 4 weeks from the end of the intervention (at follow-up). The intervention will be 4 weeks overall, with total of 8 sessions: the duration of each session will be 60 minutes each, and the frequency will be twice weekly for 4 weeks.
  • Other: Physical Activity Educational Program — The control group will serve as an sham active comparator, designed to control for group format, scheduled sessions, and social interaction. The agenda for the control group was designed to specifically function as a control to compare the A-B-C program. These participants will also attend twice-weekly 60-minute sessions over four weeks, focusing on educational content about the health benefits of physical activity and current physical activity guidelines. The difference between the two interventions is that the control program is strictly educational, whereas the A-B-C program focuses on challenging cognitive biases that change decision making related to physical activity. To reiterate, the control program simply provides education on the effects of physical activity with physiological evidence.
Eligibility Criteria
Inclusion Criteria: * 1\. All sex and gender inclusive 2. Age 65 and over 3. Cognitive telephone screening via the 20-point Tele-MoCA with a score of 16 or higher. 4\. Score on the PHQ-9 is between 2-14. 5. The participant agrees to attend all the meetings for the duration of the study, and to practice home assignments. 6\. Adequate command of English to be able to participate in the group sessions. 7. Current weekly duration of exercise\* ≤60 minutes/week. (\*Exercise: a specific type of physical activity \[PA\], which is structured, and has the intention of improving either health or fitness. Exercise differs from PA, which includes any physical effort, however without the intention of improving health or fitness \[e.g., driving, cleaning, standing, etc. are examples for PA, not exercise\]) 8. Participants have interest in increasing their weekly time of physical activity, and willingness to practice skills learned during the program. 9\. Agree to participate in any of the study groups according to a randomized allocation. Exclusion Criteria: * 1\. Acute medical condition that requires treatment. 2. Existing medical conditions that contra-indicate or limit physical activity (e.g., post-surgery, recurrent falls, etc.) 3. Unstable psychiatric condition that requires acute care. 4. Current use of psychoactive medication that might compromise balance or induce risk when performing physical activity (e.g., high dose of sedative medications) 5. Current use of recreational drug use (must be free of substance use for 12 months). 6\. Patients currently involved in routine intensive exercise\* \> 1 hour/ week. 7. Lack of interest to increase their daily time of physical activity 8. Refuse to participate in any of the study groups according to a randomized allocation. 9\. PHQ-9 score less than 2, or greater than 14.
M3VAS Validation in Polish Population
NCT06412562
Recruiting
Conditions Depressive Disorder
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Low mood and anhedonia represent the fundamental symptoms of major depressive disorder (MDD). Nevertheless, there is currently no standardized visual analogue scale available to assess the extent of both symptoms concurrently. The Maudsley 3-item Visual Analogue Scale (M3VAS) is a newly developed tool for participants to self-assess core symptoms of depression: mood quality, pleasure experience (anhedonia), and suicidality. Despite suicidality not being a primary symptom, it is included due to its critical relevance to safety. Participants will be instructed to rate the intensity and frequency of their experiences over the preceding two weeks by marking a 100 mm ungraded line. A researcher will then assign a numerical value based on the mark's position, utilizing the left edge as 0 and the right as 100. The total score range, combining the three symptoms, ranged from 0 (minimum) to 300 (maximum). The M3VAS exhibited good psychometric properties in British population. In this study, the objective is to assess the psychometric properties of the scale within the Polish population diagnosed with major depressive episode within major depressive disorder or bipolar disorder.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: The Maudsley 3-item Visual Analogue Scale (M3VAS) — Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).

Primary Outcomes

  • The Maudsley 3-item Visual Analogue Scale (M3VAS) (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-05-09
Completion: 2026-09
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Gdansk
Collaborators: King's College London
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Diagnostic Test: The Maudsley 3-item Visual Analogue Scale (M3VAS) — Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).
Study Locations (1 sites)
Medical University of Gdańsk, Gdansk, Poland
Eligibility Criteria
Inclusion Criteria: Diagnosis as provided by DSM-5 criteria: Major depressive disorder (MDD) Bipolar disorder (BD) Exclusion Criteria: Diagnosis as provided by DSM-5 criteria: Psychotic disorders Current Mania or hypomania within bipolar disorder (BD)
Dosing rTMS for Depression Post-SCI
NCT05553353
Recruiting
Conditions Spinal Cord Injuries, Depression, Depres...
Phase NA
Enrollment 24
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Depression is a leading cause of disability worldwide and is more commonly seen in individual's post-spinal cord injury (SCI) than in the general population. Depression post-SCI impacts an individuals' quality of life and recovery. It has been reported that among Veterans with an SCI, those without depression live longer than those with depression. Thus, depression must be treated appropriately. Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for depression, but dosing is based on a motor response or movement in the thumb. Over half of individuals with SCI have some degree of arm or hand impairment, so these individuals might not be eligible for rTMS, or they may receive the wrong dose. This study proposes clinical trial in individuals with depression post-SCI to assess the anti-depressant effect of a novel technique to dose rTMS that does not require a motor response in the thumb. By gaining a better understanding of the application of rTMS for depression post-SCI, the investigators aim to advance the rehabilitative care of Veterans.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: repetitive transcranial magnetic stimulation--Active — Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.
  • Device: repetitive transcranial magnetic stimulation--Sham — Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.

Primary Outcomes

  • Change from baseline in Hamilton Depression Rating Scale-17 (HAM-D17) score immediately post-intervention (Baseline; Following Week 2 of 6-week intervention Following Week 4 of 6-week intervention; Immediately post-intervention; 12-weeks post-intervention; 24-weeks post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-31
Completion: 2027-10-29
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Catherine J VanDerwerker, PhD DPT PT (PRINCIPAL_INVESTIGATOR) - Ralph H. Johnson VA Medical Center, Charleston, SC
Contact Information
Study Contact:
Catherine J VanDerwerker, PhD DPT PT
(843) 792-5047
catherine.vanderwerker@va.gov
Sarah A Jackson, BA MA
(843) 789-6700
sarah.jackson@va.gov
Interventions
  • Device: repetitive transcranial magnetic stimulation--Active — Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.
  • Device: repetitive transcranial magnetic stimulation--Sham — Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.
Study Locations (1 sites)
Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina 29401-5703 United States
Eligibility Criteria
Inclusion Criteria: * cervical or thoracic spinal cord injury at least 6 months prior with AIS A, B, C, or D; * 18 - 60 years of age; * major depressive disorder, as identified by Structured Clinical Interview for DSM-V; * Hamilton Depression Rating Scale-17 score \> 18; * not taking antidepressant medications or no change in doses of psychotropic medication(s) for at least 4 weeks before the study (6 weeks if newly initiated medication) Exclusion Criteria: * concomitant neurologic diseases/disorders or dementia; * cognitive impairment (Montreal Cognitive Assessment \<17); * history of psychosis or other Axis I disorder that is primary; * positive screen for bipolar disorder through the Mini-International Neuropsychiatric Interview; * history of claustrophobia; * life expectancy \<1 year; * electronic or metallic implants (i.e., metal in the head, cochlear implant, or pacemaker; * history of seizures or currently prescribed anti-seizure medications; * taking medication that increases the risk of seizures; * pregnancy as identified through a positive urine pregnancy test; * Hamilton Depression Rating Scale-17 question #3 regarding suicide: \>2 or suicide attempt within the previous two years; * inability to (University of California, San Diego Brief Assessment of Capacity to Consent) or declined to give informed consent.
School-Based Intervention to Enhance Resilience and Stress Coping in Rural Chinese Adolescents
NCT07115186
Recruiting
Conditions Stress, Emotional, Stress-related Mental...
Phase NA
Enrollment 850
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the effectiveness of school-based psychological interventions in improving stress resilience and coping skills among adolescents in rural China. The intervention seeks to reduce stress-related mental health symptoms, including depression, anxiety, and post-traumatic stress, measured using validated instruments such as the Patient Health Questionnaire-9 (PHQ-9), the Generalized Anxiety Disorder 7-item scale (GAD-7), and the Child PTSD Symptom Scale for DSM-5 (CPSS-5). (See Appendix for full scale descriptions.) Participants will be recruited from rural middle schools and randomly assigned to either an intervention group or a wait-list control group. The intervention consists of four sessions delivered over one week. Assessments will be conducted at baseline, immediately after the intervention, and again at a 3-month and 6-month follow-ups. Researchers will use multilevel modeling (MLM) and structural equation modeling (SEM) to examine potential mediators and moderators of intervention effects, including emotion recognition, alexithymia, and coping strategies. indings are expected to provide evidence on the effectiveness and mechanisms of an existing, school-based psychological intervention tailored to the needs of adolescents in underserved rural settings.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Psychoeducation — Psychoeducation sessions for adolescents focus on essential topics like stress, emotional distress, and mental disorders, offering foundational knowledge to enhance their understanding and ability to manage these challenges effectively.
  • Behavioral: guided written therapy — In the guided writing intervention, students are asked to write about a recent event that triggered strong emotions on paper and, based on the requirements of each session, attempt to regulate their emotions. This approach aims to enhance students' abilities in emotional identification and emotion regulation.
  • Behavioral: wait-list condition — Participants will engage in their regular school activities, and after the intervention group completes the program, they will receive the same intervention content as the intervention group.

Primary Outcomes

  • PTSD for adolescents (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
  • Depression (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
  • Insomnia Severity (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
  • Generalized anxiety disorder (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
  • Alexithymia (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
  • Emotion awareness (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-12
Completion: 2026-12-31
Eligibility
Age: 10 Years
Sex: ALL
Volunteers: true
Enrollment: 850 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University
Contact Information
Study Contact:
Zang Yinyin, PhD
+86 15553201610
yinyin.zang@pku.edu.cn
Feng Junkai, MSc
86+15625013745
Interventions
  • Behavioral: Psychoeducation — Psychoeducation sessions for adolescents focus on essential topics like stress, emotional distress, and mental disorders, offering foundational knowledge to enhance their understanding and ability to manage these challenges effectively.
  • Behavioral: guided written therapy — In the guided writing intervention, students are asked to write about a recent event that triggered strong emotions on paper and, based on the requirements of each session, attempt to regulate their emotions. This approach aims to enhance students' abilities in emotional identification and emotion regulation.
  • Behavioral: wait-list condition — Participants will engage in their regular school activities, and after the intervention group completes the program, they will receive the same intervention content as the intervention group.
Study Locations (1 sites)
Biancun middle school, Hebei, Baoding 071603 China
Eligibility Criteria
Inclusion Criteria: * Currently enrolled middle school students attending regular school classes * Sufficient functional capacity in hearing, speaking, reading, and writing to participate in intervention activities and assessments. Exclusion Criteria: * Individuals assessed to be at high risk of suicide, based on screening or clinical judgment * Diagnosis of severe mental disorders (e.g., psychotic disorders, severe mood disorders) that would interfere with participation or require more intensive clinical care
Mediterranean Diet and the Microbiota Gut Brain Axis in Major Depression
NCT04772651
Not yet recruiting
Conditions Depression
Phase NA
Enrollment 108
Locations 0 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the efficacy of a Mediterranean diet on the function of the vagal nerve in patients with depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Mediterranean Diet — Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)
  • Other: Normal hospital diet — Normal hospital diet
  • Other: dietary coaching — dietary coaching
  • Other: Psychoeducation on depression — Psychoeducation on depression (50minutes once a week for 4 weeks)

Primary Outcomes

  • Change in Vagal function (at study entry, after 7 days, after 4 weeks and after 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2025-11-01
Completion: 2029-09-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 108 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Graz
Contact Information
Study Contact:
Sabrina Mörkl, DDr.
004331638581743
sabrina.moerkl@medunigraz.at
Eva Reininghaus, Prof.
eva.reininghaus@medunigraz.at
Interventions
  • Other: Mediterranean Diet — Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)
  • Other: Normal hospital diet — Normal hospital diet
  • Other: dietary coaching — dietary coaching
  • Other: Psychoeducation on depression — Psychoeducation on depression (50minutes once a week for 4 weeks)
Eligibility Criteria
Inclusion Criteria: * legally competent persons aged 18-80 years * diagnosis of depression according to ICD-10 or DSM. Exclusion Criteria: * other neurologic or psychiatric disorders (epilepsy, brain tumor, head injury, head surgery, trauma) * drug or alcohol dependency * acute suicidality * heart disorders, disorders of the circulatory system * pregnancy and period of breastfeeding * severe mental disability, dementia (MMST\<20) * autoimmune disorder, severe immunosuppression (Lupus, HIV, multiple sclerosis) * therapy with antibiotics in the last month * chronic laxative abuse * acute infectious diarrhea * GI surgeries (except appendectomy) * regular intake of probiotics, antibiotics and food supplements (1 month before and during the study) * food allergies or other food intolerances which are incompatible with a mediterranean diet * vegetarians, vegans
Brain Stimulation and Decision-making
NCT04099056
Recruiting
Conditions Depression
Phase NA
Enrollment 500
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Decision-making is an important process that is frequently shown to be impaired in patients with depression. While a number of preclinical and clinical studies have identified key regions involved in this process, it remains unclear exactly how these regions are influencing choice behavior especially when choices become more challenging. The goal of this project is to understand how these regions, such as the cingulate cortex, impact difficult choice behavior. Specifically, the researchers are interested in learning how disruptions in cognitive control might impact choice preferences during difficult decisions in depressed patients. To do this, this study will recruit participants with depression (as well as healthy controls) to perform game-like tasks in the laboratory while undergoing TMS or TI.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Device: Neurostimulation — Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Participants will receive neurostimulation in the form of Transcranial Magnetic Stimulation (TMS) or Temporal Interference (TI). TMS: Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks. TI: Either during, or just before, any of the above tasks, participants will receive stimulation with TI. To do so, commercially available gel-based electrodes will be placed on the scalp to target the relevant brain region. The position targeted by the electrodes will be guided by previously defined coordinates.

Primary Outcomes

  • Staggered Effort-Based Decision-Making Task (Day 1, during TMS/ TI stimulation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-11-11
Completion: 2028-03
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Michael Treadway, PhD (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Michael Treadway, PhD
404 727-3166
tread.lab.cbid@emory.edu
Interventions
  • Device: Neurostimulation — Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Participants will receive neurostimulation in the form of Transcranial Magnetic Stimulation (TMS) or Temporal Interference (TI). TMS: Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks. TI: Either during, or just before, any of the above tasks, participants will receive stimulation with TI. To do so, commercially available gel-based electrodes will be placed on the scalp to target the relevant brain region. The position targeted by the electrodes will be guided by previously defined coordinates.
Study Locations (1 sites)
Emory University, Atlanta, Georgia 30322 United States
Eligibility Criteria
Inclusion Criteria: * Provides written informed consent * Fluent English speaker * Absence of current drug use as assessed by subject history and/or urine drug screen Exclusion Criteria: * Pregnant or currently breastfeeding women or any woman of childbearing potential who is seeking to become pregnant or suspects that she may be pregnant, as assessed by subject report and/or urine pregnancy screen * Contraindications to fMRI scanning (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia) as assessed with the standard MRI screening form from the Facility for Research and Education in Neuroscience (FERN) * Unable to fit comfortably in the scanner * Contraindication to TMS, including history or family history of epilepsy, metallic implants in the head and/or neck, brain stimulators, vagus nerve stimulators, ventriculoperitoneal (VP) shunt, pacemakers * Current use of medications that may increase the risk of seizures (e.g., bupropion, varenicline, chlorpromazine, theophylline) or reduce the effects of rTMS, such as benzodiazepines * History or current serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease, as assessed by subject history * Not right-handed as assessed by the Chapman handedness inventory or self-report * History of head injury resulting in more than a brief loss of consciousness, as assessed by subject history * History of cocaine or stimulant use (e.g., amphetamine, cocaine, methamphetamine), as assessed by subject history * History of use of dopaminergic drugs (including methylphenidate or other stimulant medication), as assessed by subject history * Current use or more than occasional use in the past year of tobacco products, including cigarettes, e-cigarettes, cigars, snuff, and chewing tobacco, or nicotine replacement products such as gum or patches, as assessed by subject history * Evidence of significant inconsistencies in self-report measures Additional Exclusion Criteria for Optional Ecological Momentary Assessment (EMA)Component for Subject Safety * Anything above minimal risk for suicide, as assessed during the clinical interview (SCID) at screening and the Columbia Suicide Severity Rating Scale (C-SSR). C-SSRS risk will be assessed as any score \> 3. * Any physical or neuropsychiatric conditions that may worsen/or prevent walking or running. Additional Exclusion Criteria for Optional Ecological Momentary Assessment (EMA)Component for Data Quality * Meet criteria for current psychotic disorders, bipolar disorders, or severe substance use disorders as assessed by the Mini International Neuropsychiatric Interview. * Used psychotropic medications within the last six weeks as assessed by subject history. Additional Exclusion Criteria for Participants with Major Depressive Disorder: * Anything above minimal risk for suicide, as assessed during the clinical interview (SCID) at screening and the Columbia Suicide Severity Rating Scale (C-SSRS) * A symptom severity score of at least 11, as assessed by the Beck Depression Inventory (BDI)-II * History or current diagnosis of any of the following Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV psychiatric illnesses: * Organic mental disorder * Schizophrenia spectrum disorders * Delusional disorder * Psychotic disorders not otherwise specified * Patients with mood-congruent or mood-incongruent psychotic features * Patients with bipolar mood disorders * Substance dependence * Substance abuse within the last 12 months (except cocaine or stimulant abuse), which will lead to exclusion * Absence of any psychotropic medications for at least 2 weeks. No patient will be asked to discontinue or otherwise interrupt any psychotropic medications to participate in this study. The listed "washout" periods are only applicable for patients who previously used psychotropic medications, but recently decided to discontinue their use for some other reason. * 6 weeks for fluoxetine * 6 months for neuroleptics * 2 weeks for benzodiazepines * 2 weeks for any other antidepressants Additional Exclusion Criteria for Healthy Controls: * Any current or past history of any DSM-IV psychiatric illnesses, presence of a DSM-IV psychiatric disorder within a first-degree relative, or current or past use of psychotropic medications * Score no greater than 10 on the BDI-II * Score \> 1 on the SHAPS
Prevention of Mental Disorders Through Self-efficacy Interventions
NCT06738953
Recruiting
Conditions Depression Disorders, Affective Disorder...
Phase NA
Enrollment 378
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Low self-efficacy is a transdiagnostic risk factor for several mental disorders. Self-efficacy refers to one's belief that one is capable of performing a behavior necessary to successfully complete a task or achieve a goal. Consistent with theoretical models and empirical findings, individuals with low self-efficacy are more likely to perceive challenges as uncontrollable and threatening and thus are at increased risk for developing mental disorders during sensitive periods such as young adulthood. Self-efficacy interventions have been shown to be effective in promoting health behavior change, quality of life, and treatment adherence in patients with serious illnesses, as well as motivation and performance in students and employees. However, whether targeted self-efficacy training can prospectively prevent the onset of full-threshold anxiety, affective, and substance use disorders in young adults at increased risk for psychopathology remains an open question. The aim of this randomized controlled trial is to test whether a brief cognitive-behavioral intervention in young adults with low self-efficacy can increase general self-efficacy (primary outcome of intervention effectiveness) and thus prevent the onset of DSM-5 mental disorders in the subsequent year (primary outcome of prevention effectiveness). In addition, we examine whether improvements in domain-specific self-efficacy lead to subsequent improvements in general self-efficacy and thus to lower psychopathological symptoms (spillover effects). Young adults (18-30 years) with low self-efficacy but no mental disorder will be included (N=378). The study will include screening, entry, baseline, post, and 12-month follow-up assessments plus additional course assessments in both groups. After the baseline assessment, participants will be randomized to an intervention or control group. The intervention group will receive group-based self-efficacy training (6 sessions of 75-90 minutes each). The control group will also meet in groups (6 sessions) but will only talk about psychological research findings unrelated to self-efficacy or cognitive-behavioral interventions without receiving any training. DSM-5 mental disorders will be assessed at study entry and follow-up with a structured diagnostic interview. Other outcomes will be assessed with established scales and ecological momentary assessments (EMA) at baseline, post and follow-up. Clinical outcomes include psychopathological symptoms (dimensional scores for anxiety, depression, anger, and somatic symptoms, as well as sleep disturbance) and mental disorders (DSM-5 categorical diagnoses of anxiety, affective, and substance use disorders). Intervention effectiveness will be tested using logistic/linear regression and multilevel analyses. Spillover effects between improvements in domain-specific/general self-efficacy and psychopathological symptoms over the course of the study will be examined using cross-lagged panel models.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Cognitive-Behavioral Intervention to increase Self Efficacy — Participants in the intervention group will receive a brief (6 sessions of 75-90 min each) cognitive-behavioral intervention. The intervention will be delivered in an online group format (subgroups of 8-12 participants). The courses will be structured according to well-established self-efficacy interventions with proven effectiveness (Bresó et al., 2011; Cieslak et al., 2016; Luszczynska et al., 2007), targeting Bandura's four key sources of self-efficacy (i.e., mastery experience, vicarious experience, verbal persuasion, and physiological/emotional arousal). Each session will consist of a theoretical and a practical part and be structured as follows: opening, discussion of homework (with special emphasis on participants' progress and sharing of experiences), introduction to the topic, practice, answering open questions, closing. The course sessions are accompanied by weekly homework assignments to be completed at home.
  • Behavioral: Placebo: Weekly Recap and Group Discussion on Psychological Experiments — Participants in the control group will meet in small groups (8-12 participants per group; 6 sessions, similar to the intervention group). They will receive a brief introduction to well-known psychological experiments and findings (e.g., the Asch experiment, selective attention) and discuss their perspectives on these topics, including personal implications of the experiments. Content related to self-efficacy or cognitive-behavioral interventions will be explicitly avoided. To prevent expectancy effects and other biases, participants will not be informed that they are part of the control group. If suspicions arise, participants will be told that group leaders are not allowed to disclose this. Group sessions will be led by a psychologist. The course materials (workbook, slides, and course instructions) will be shared on OSF.

Primary Outcomes

  • Change in general self-efficacy measured by the German version of the General Self-Efficacy Scale (GSE) (From baseline to post (approximately 8-10 weeks).)
  • Rates of incident DSM-5 mental disorders assessed by the SCID-CV. (From baseline to follow-up (approximately 14 months).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-18
Completion: 2026-04-20
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 378 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Health and Medical University Potsdam
Collaborators: German Research Foundation, Charite University, Berlin, Germany
Contact Information
Study Contact:
Eva Asselmann, Prof. Dr. rer. nat. habil.
+49 331 74 51 13 131
eva.asselmann@health-and-medical-university.de
Felix D Gross, M. Sc. Psychology
+49 331 74 51 13 131
felix.gross@hmu-potsdam.de
Interventions
  • Behavioral: Cognitive-Behavioral Intervention to increase Self Efficacy — Participants in the intervention group will receive a brief (6 sessions of 75-90 min each) cognitive-behavioral intervention. The intervention will be delivered in an online group format (subgroups of 8-12 participants). The courses will be structured according to well-established self-efficacy interventions with proven effectiveness (Bresó et al., 2011; Cieslak et al., 2016; Luszczynska et al., 2007), targeting Bandura's four key sources of self-efficacy (i.e., mastery experience, vicarious experience, verbal persuasion, and physiological/emotional arousal). Each session will consist of a theoretical and a practical part and be structured as follows: opening, discussion of homework (with special emphasis on participants' progress and sharing of experiences), introduction to the topic, practice, answering open questions, closing. The course sessions are accompanied by weekly homework assignments to be completed at home.
  • Behavioral: Placebo: Weekly Recap and Group Discussion on Psychological Experiments — Participants in the control group will meet in small groups (8-12 participants per group; 6 sessions, similar to the intervention group). They will receive a brief introduction to well-known psychological experiments and findings (e.g., the Asch experiment, selective attention) and discuss their perspectives on these topics, including personal implications of the experiments. Content related to self-efficacy or cognitive-behavioral interventions will be explicitly avoided. To prevent expectancy effects and other biases, participants will not be informed that they are part of the control group. If suspicions arise, participants will be told that group leaders are not allowed to disclose this. Group sessions will be led by a psychologist. The course materials (workbook, slides, and course instructions) will be shared on OSF.
Study Locations (1 sites)
Health and Medical University Potsdam, Potsdam, Brandenburg 14471 Germany
Eligibility Criteria
Inclusion Criteria: 1. age 18-30 years and 2. low scores (≤24) on the German version of the General Self-Efficacy Scale (i.e., more than one standard deviation (5.4) below the mean score of 29.4 in the German norm sample; The cutoff will be raised to scores below the mean of 29.4 (≤30) if not enough participants with low self-efficacy scores of ≤24 and without 12-month mental disorders are found and this leads to serious problems regarding the recruitment phase and the timeline of the project. 3. ability to participate in the course (German language proficiency, availability during the intervention period) Exclusion Criteria: 1. 12-month anxiety, affective, or substance use disorder (excluding nicotine dependence) 2. current psychological/psychopharmacological intervention or treatment seeking for psychological problems 3. acute suicidality; Individuals who report acute suicidality will be withdrawn from the study and referred to treatment.
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
NCT06136546
Recruiting
Conditions Depressive Disorder, Major, Inflammation
Phase PHASE2
Enrollment 100
Locations 1 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Infliximab — Intravenous infusion of infliximab
  • Other: Placebo — Intravenous infusion of saline solution (matching in color and consistency in infliximab)

Primary Outcomes

  • Psychomotor Speed (TestMyBrain: Simple Reaction Time) (Repeated measures over two weeks)
  • Executive Function (TestMyBrain: Choice Reaction Time) (Repeated measures over two weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-23
Completion: 2029-01-31
Eligibility
Age: 25 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Contact Information
Study Contact:
Naoise Mac Giollabhui, PhD
6177241000
nmacgiollabhui@mgh.harvard.edu
Interventions
  • Drug: Infliximab — Intravenous infusion of infliximab
  • Other: Placebo — Intravenous infusion of saline solution (matching in color and consistency in infliximab)
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: 1. Aged 25-50 years 2. Able to read and understand English and willing to provide informed consent/comply with the study protocol 3. Willingness to complete intravenous infusion and have blood drawn 4. Exhibit circulating blood level of C reactive protein ≥ 3mg/L 5. Diagnosed with Major Depressive Disorder 6. Moderate depressive symptom severity, as indicated by score ≥15 on the Hamilton Depression Rating Scale 7. Antidepressant treatment free for at least 4 weeks prior to study entry or be on a fixed treatment regimen for at least 4 weeks; willingness to continue treatment status (i.e., change/begin new treatment) until study termination 8. Willingness not to begin/change therapies until study termination (maximum of three weeks following screening) 9. Be of non-childbearing potential per the following specific criteria: a. Non-childbearing potential (e.g., physiologically incapable of becoming pregnant, i.e., permanently sterilized (status post hysterectomy, bilateral tubal ligation), or is post-menopausal with her last menses at least one year prior to screening); or b. Childbearing potential and meets the following criteria: i. A negative serum pregnancy test within thirty days of infusion (may be repeated closer to infusion date at the discretion of the PI or study staff) and abstinent after the negative serum pregnancy test and prior to infusion; or ii. Using any form of hormonal birth control, on hormone replacement therapy started prior to 12 months of amenorrhea, using an intrauterine device (IUD), having a monogamous relationship with a partner who has had a vasectomy, or is sexually abstinent; iii. Continuously use one of the following methods of birth control over the last six months: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. Exclusion Criteria: 1. Medical conditions that could confound interpretation or increase participant risk, as indicated via medical history or laboratory testing; exclusionary medical conditions will include: i. acute injury/infection within one week of study initiation or infection within one month of study initiation that required antibiotic/antiviral treatment ii. chronic infection (e.g., hepatitis B or C or HIV) or history of Covid 19 infection within the past 6 months or with persisting symptoms. iii. latent infection (e.g., tuberculosis, fungal infections), or history of recurrent infections, iv. uncontrolled cardiovascular, endocrine, hematologic, hepatic, renal or neurologic disease (as determined by medical history, physical exam and laboratory testing) v. cancer history vi. autoimmune conditions; neurologic conditions (controlled) that are known to substantially impact cognitive function (e.g., stroke). Of note, stable medical conditions such as diabetes and cardiovascular disease, will be allowed in the study as they can contribute to endogenous inflammation. 2. Active antipsychotic and anticonvulsant medication use (that interact with infliximab) 3. Prior use of a TNF antagonist or use of systemic corticosteroids or anti-proliferative agents within one year of study entry 4. History of liver abnormalities 5. Major cognitive impairment as determined by study investigators 6. Active restrictive eating disorder or obsessive compulsive disorder deemed by study investigators to be primary cause of depressive disorder 7. History of a psychotic disorder or Bipolar disorder type I/II 8. Current substance use disorder (i.e., present in last six months), of greater than mild severity 9. Suicidal ideation based on a score ≥3 on the Columbia-Suicide Severity Rating Scale 10. Electroconvulsive therapy (ECT)/deep brain stimulation (DBS) within the last year, or report of persistent negative cognitive effects of ECT/DBS 11. Presence of a transplanted solid organ 12. Medication use affecting immune or cognitive function: i. Chronic use (\>1 month) of a benzodiazepine more than the equivalent of 2 mg of lorazepam ii. Use of anti-inflammatory agents during the study: non-steroidal anti-inflammatory agents (NSAIDs) (excluding 81mg of aspirin), glucocorticoid containing medicines or statins, or cyclooxygenase-2 (COX-2) inhibitors 13. Considered by the study investigators to be inappropriate for the study due to safety concerns or to be unlikely to complete the protocol 14. History of allergic response to murine products
EEG-based Neurofeedback to Improve Emotion Regulation in Major Depressive Disorder: A Randomized Clinical Trial
NCT07041073
Recruiting
Conditions Major Depression With Comorbid Anxiety S...
Phase NA
Enrollment 72
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate whether EEG-based neurofeedback targeting the emotion regulation network through swLORETA can improve emotional regulation and reduce symptoms in adults with Major Depressive Disorder (MDD) who have not responded sufficiently to first-line treatments. The main questions it aims to answer are: * Does EEG-neurofeedback improve emotional self-regulation and reduce clinical symptoms in patients with MDD with or without anxiety symptoms? * Are changes in EEG resting-state activity and stress biomarkers (e.g., cortisol) associated with clinical improvement? Researchers will compare an active neurofeedback group, a sham (placebo) neurofeedback group, and a treatment-as-usual control group to see if real-time EEG-neurofeedback leads to greater improvement in mood, emotional regulation, and neurophysiological indicators than placebo or no additional intervention. Participants will: * Receive 10 sessions of either real or sham EEG-neurofeedback (or no sessions in the control group) over 5 weeks. * Complete clinical, psychological, and neurophysiological assessments before (week 0) and after the intervention (week 6). * Provide repeated saliva samples to assess stress-related biomarkers at week 0 and week 6. * Continue their standard pharmacological treatment throughout the study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Active swLORETA Z-score Neurofeedback — Participants receive 10 sessions (25 minutes each, twice per week for 5 weeks) of EEG-based neurofeedback using the NeuroGuide® software and a 24-channel EEG recording system (eego™, ANT Neuro). The neurofeedback protocol is based on real-time swLORETA Z-score training targeting brain regions involved in emotion regulation. Feedback is provided via gamified visual displays when EEG activity moves toward normative patterns. This is an operant conditioning-based protocol designed to enhance emotional self-regulation.
  • Device: Yoked-sham swLORETA Z-score Neurofeedback — Participants receive 10 sessions identical in appearance and duration to the active neurofeedback condition. However, the feedback provided is not based on their own EEG activity. Instead, it is pre-recorded data from a matched participant in the active group ("yoked" design), ensuring no real-time neurophysiological modulation occurs. The same EEG equipment and visual feedback interface are used to maintain blinding.

Primary Outcomes

  • Change in depressive symptom severity, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), from baseline to post-intervention. (From enrollment (week 0) to the end of treatment (week 6))
  • Change in depressive symptoms measured by the Hamilton Depression Rating Scale (HAM-D), from baseline to post-treatment (From enrollment (week 0) to the end of treatment (week 6))
  • Change in self-reported anxiety symptoms measured by the Beck Anxiety Inventory (BAI), from baseline to post-intervention (From enrollment (week 0) to the end of treatment (week 6))
  • Change in self-reported depressive symptoms measured by the Beck Depression Inventory-II (BDI-II), from baseline to post-intervention (From enrollment (week 0) to the end of treatment (week 6))
  • Change in salivary cortisol levels (Cortisol Awakening Response and Diurnal Slope) (From enrollment (week 0) to the end of treatment (week 6))
  • Change in cognitive emotion regulation strategies measured by the Cognitive Emotion Regulation Questionnaire (CERQ) (From enrollment (week 0) to the end of treatment (week 6))
  • Change in transient mood states measured by the Profile of Mood States (POMS) (Before and after each neurofeedback session (Sessions 1-10; Weeks 1-5))
  • Change in resting-state EEG activity (From baseline (week 0) to Post-treatment (Week 6); Before and after each neurofeedback session (Sessions 1-10; Weeks 1-5))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-19
Completion: 2026-09
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Corporacion Parc Tauli
Collaborators: Horizon 2020 - European Commission
Contact Information
Study Contact:
Virginia Soria, MD,PhD
+34 937231010
vsoria@gmail.com
Diego Palao, MD, PhD
+34 937231010
dpalao@tauli.cat
Interventions
  • Device: Active swLORETA Z-score Neurofeedback — Participants receive 10 sessions (25 minutes each, twice per week for 5 weeks) of EEG-based neurofeedback using the NeuroGuide® software and a 24-channel EEG recording system (eego™, ANT Neuro). The neurofeedback protocol is based on real-time swLORETA Z-score training targeting brain regions involved in emotion regulation. Feedback is provided via gamified visual displays when EEG activity moves toward normative patterns. This is an operant conditioning-based protocol designed to enhance emotional self-regulation.
  • Device: Yoked-sham swLORETA Z-score Neurofeedback — Participants receive 10 sessions identical in appearance and duration to the active neurofeedback condition. However, the feedback provided is not based on their own EEG activity. Instead, it is pre-recorded data from a matched participant in the active group ("yoked" design), ensuring no real-time neurophysiological modulation occurs. The same EEG equipment and visual feedback interface are used to maintain blinding.
Study Locations (1 sites)
Corporació Sanitària Parc Taulí de Sabadell, Sabadell, Barcelona, Cataluña 08208 Spain
Eligibility Criteria
Inclusion Criteria: * A primary diagnosis of Major Depressive Disorder (MDD), established by qualified psychiatrists according to DSM-5 criteria. * Patients with comorbid anxiety or anxiety symptoms will be included, provided that MDD is the primary diagnosis. * Participants must score at least 20 on the Montgomery-Åsberg Depression Rating Scale (MADRS), indicating a moderate level of depression. * All participants must be on a stable psychopharmacological treatment for at least 6 weeks before beginning of the study. Exclusion Criteria: * Patients with a concurrent diagnosis of MDD and other severe psychiatric disorders. * Patients with serious physical illnesses that could interfere with study participation or the interpretation of results. * Participants currently undergoing structured psychotherapy or other interventions unrelated to standard psychopharmacological treatment. * Patients presenting with active suicidal ideation, as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS), at the time of screening will not be eligible due to associated risks. * Active substance abuse or dependence (except nicotine). * Intellectual disability or conditions that interfere with the ability to provide informed consent and complete the intervention (e.g., severe visual or hearing impairments). * Pregnancy.
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Active, positions filled
Conditions Major Depressive Disorder
Phase PHASE3
Enrollment 1000
Locations 178 sites
Compensation Phase 3: Typically $200-$1,000
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: NMRA-335140 — Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.

Primary Outcomes

  • Safety and tolerability assessments based on Treatment Emergent Adverse Events (TEAEs) and validated clinical scales (Up to 54 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Active, positions filled
Start Date: 2023-11-10
Completion: 2027-06
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Neumora Therapeutics, Inc.
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Drug: NMRA-335140 — Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.
Study Locations (178 sites)
Neumora Investigator site, Huntsville, Alabama 35801 United States
Neumora Investigator Site, Phoenix, Arizona 85012 United States
Neumora Investigator Site, Bentonville, Arkansas 72712 United States
Neumora Investigator Site #1, Little Rock, Arkansas 72211 United States
Neumora Investigator site, Little Rock, Arkansas 72211 United States
Neumora Investigator Site, Rogers, Arkansas 72758 United States
Neumora Investigator site, Bellflower, California 90706 United States
Neumora Investigator Site, Cerritos, California 90703 United States
Neumora Investigator Site, Encino, California 91316 United States
Neumora Investigator Site, Garden Grove, California 92845 United States
Eligibility Criteria
Key Inclusion Criteria: Rollover participants are eligible for the study if the following inclusion criteria are met: * Completed a previous NMRA-335140 Phase 3 MDD study (example: NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303) according to the completion definition in the parent study protocol. * Signed an informed consent form (ICF) for this study. * Willing to comply with the contraception requirements described in the inclusion criteria of the parent study protocol. * Willing to comply with the concomitant medication/therapy restrictions described in the exclusion criteria of the parent study protocol. Key Exclusion Criteria: Rollover participants are excluded from the study if any of the following exclusion criteria are met: * Diagnosed with another Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) disorder that would have been exclusionary in the parent study (eg, personality disorder, bipolar 1 or 2, schizophrenia, any other psychotic disorder, or moderate or severe substance or alcohol use disorder \[excluding nicotine\]). * Considered to be at significant risk of suicide in the judgment of the Investigator. This includes participants who are actively suicidal (eg, any suicide attempts during the parent study) or are at serious suicidal risk as indicated by any current suicidal intent, including a plan, as assessed by the C-SSRS ("Since Last Visit" version, score of "YES" on suicidal ideation Item 4 or 5) and/or based on clinical evaluation by the Investigator; or are homicidal, in the opinion of the Investigator. * Non-adherent with study medication (took ≤70% of study drug over any 2-week visit interval) or procedures during the parent study. * Experienced treatment emergent adverse events (TEAEs) considered related to the study medication from the parent study and judged by the Investigator to be clinically significant to render the participant ineligible for enrollment. * Have an abnormality on ocular examination that would prohibit continued study participation as determined by the Investigator. * Use of disallowed concomitant medication or therapy that would have been exclusionary in the parent study, may compromise the safety of the participant, and/or confound the interpretation of protocol assessments. * Considered by the Investigator to be inappropriate for any other reason.
Biomarkers of Depression and Treatment Response
NCT04581902
Recruiting
Conditions Depressive Disorder, Major
Phase NA
Enrollment 50
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study is a stratified, parallel-group, single-center study utilizing multimodal imaging techniques to identify biomarkers for Major Depressive Disorder (MDD). The study goal is to identify biomarkers for MDD and treatment response that can be implemented in clinical diagnosis and care as valid and reliable measures, through monitoring neurophysiological and electrophysiological changes across the course of transcranial magnetic stimulation (TMS) treatment.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: rTMS therapy — rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.

Primary Outcomes

  • Change in MADRS score from baseline to end of treatment (Up to one month prior to initial TMS session (baseline) to within one month following the completion of TMS treatment (~ 8 weeks))
  • Change in resting state BOLD signal from baseline to end of treatment (Up to one month prior to initial TMS session (baseline) to within one month following the completion of TMS treatment (~ 8 weeks))
  • Change in resting state EEG from baseline to end of treatment (Up to one month prior to initial TMS session (baseline) to within one month following the completion of TMS treatment (~ 8 weeks))
  • Change in white matter integrity from baseline to end of treatment (Up to one month prior to initial TMS session (baseline) to within one month following the completion of TMS treatment (~ 8 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-12-01
Completion: 2027-09
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Principal Investigators:
  • Andrew Krystal, MD, MS (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Katherine Scangos, MD, PhD
415-476-7439
brainstim@ucsf.edu
Rebecca Martinez, MS
rebecca.martinez@ucsf.edu
Interventions
  • Device: rTMS therapy — rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.
Study Locations (1 sites)
University of California, San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-70 * Meet Diagnostic and Statistical Manual-V (DSM-V) diagnostic criteria for Major Depressive Disorder in a current major depressive episode, without psychotic features. * Has Montgomery-Asberg Depressive Rating Scale (MADRS) of \> 19 at baseline, corresponding with moderate to severe depression. * Demonstrate a moderate level of resistance to antidepressant treatment in the current episode, defined as a failure of 1-4 adequate medication trials. * If participant is on a regimen of psychotropic medication, no changes in this regimen should be made during the period between the time at which pre-treatment and post-treatment scans are taken. * Willing and able to undergo non-invasive brain stimulation * Willing and able to attend research visits for approximately 8 weeks * Willing and able to provide informed consent * Ability to speak and read English Exclusion Criteria: * Diagnosed with acute or chronic psychotic symptoms of disorders (e.g. schizophrenia, schizophreniform, schizoaffective disorder) in the current depressive episode. * Has neurological conditions including epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system. * Presence of an implanted magnetic-sensitive medical device in or near the head, including but not limited to pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents. * Generalized anxiety disorder as the primary DSM-V disorder during the current MDD episode. * Meets criteria for alcohol or substance abuse or dependence (other than caffeine) in previous 6 months, as determined by the SCID * History of seizures * Implantable hardware not compatible with MRI or with the study * Inability to comply with study daily visits * Women who are pregnant, plan to become pregnant, or breast feeding * Inability to speak and/or read English * Inability to give consent * Any active suicidal intent or plan during the current depressive episode, as determined by a score of 3 on Question #9 of Beck's Depression Inventory (scores reviewed daily by study team members versed in scoring clinical scales), or as by a subjective determination by a study clinician during any study visit.
Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes
NCT04743466
Active, positions filled
Conditions Anxiety Disorder, Depression, Genetic Di...
Phase Not Applicable
Enrollment 1
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-13
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the association between testosterone levels and risk of dementia and adverse mental health outcomes (e.g. depression and anxiety). It is not known whether low testosterone levels may be associated with an increased risk of dementia. Learning about the association between testosterone levels and risk of dementia may help determine the long-term effects of androgen deprivation therapy and may help improve quality of life.

Design

Study type: Observational Observational model: Case Control Time perspective: Retrospective

Interventions / Regimen

  • Other: Electronic Health Record Review — Biobank records are reviewed

Primary Outcomes

  • Association between germline genetic predictors (single nucleotide variants) of lower testosterone levels and dementia risk (Up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Active, positions filled
Start Date: 2020-02-13
Completion: 2028-11-30
Eligibility
Age: No restriction
Sex: ALL
Volunteers: true
Enrollment: 1 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Kevin Nead (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Other: Electronic Health Record Review — Biobank records are reviewed
Study Locations (1 sites)
M D Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Have volunteered to participate in institutional or national biobanks, mainly the UK Biobank and the Kaiser Permanente Research Bank, and those that have previously participated in studies that resulted in de-identified clinical and genetic data being make available on public archives, mainly the database of Genotypes and Phenotypes (dbGaP) * No special populations (adults unable to consent, individuals not yet adults, pregnant women, or prisoners)